-
公开(公告)号:US20230127087A1
公开(公告)日:2023-04-27
申请号:US17774601
申请日:2020-11-06
发明人: Jo Woon Yi Lee , Youndong Kim , Da Som Lee , Jeong Kyun Lee , Daekyun Lee , So Ryong Lim
IPC分类号: C12N15/115 , C12N15/11 , A61P35/00 , A61P1/16 , A61K31/7068 , A61K31/282 , A61K33/243 , A61K31/4545 , A61K31/675 , A61K31/337 , A61K31/704 , A61K31/519 , A61K31/404 , A61K31/475
摘要: Provided are a glypican-3 (GPC3)-specific modified aptamer, and prevention or treatment of hepatoma using the same. The glypican-3-specific modified aptamer of the present invention specifically binds to glypican-3 to be internalized into hepatoma cells, and exhibits anticancer activity through an anticancer agent bound to the aptamer, and therefore, has a selective anticancer effect only for GPC3-expressing hepatoma cells without affecting normal hepatocytes.
-
公开(公告)号:US20230065158A1
公开(公告)日:2023-03-02
申请号:US17893698
申请日:2022-08-23
发明人: John S. KOVACH , Ravi SALGIA
IPC分类号: A61K31/4995 , A61K39/395 , A61K31/7048 , A61K31/282 , A61P35/00 , A61P11/00
摘要: The present invention provides a method of treating a subject suffering from SCLC comprising administering to the subject an effective amount of a PP2A inhibitor and optionally one or more anti-cancer agents.
-
公开(公告)号:US20230033582A1
公开(公告)日:2023-02-02
申请号:US17788671
申请日:2020-12-24
IPC分类号: A61K39/145 , A61K39/215 , A61K39/245 , A61K9/51 , A61K38/05 , A61K31/4709 , A61K31/47 , A61K33/06 , A61K31/4439 , A61K31/513 , A61K31/282 , A61K31/4745 , A61K31/519 , A61K31/7068 , A61K39/395 , A61P35/00
摘要: There is provided polymeric nanoparticles with non-tumour antigen payloads for use in tagging cells for destruction by a subject's immune system and the use thereof for the treatment of cancer. Suitably there is provided a method of treatment comprising administration of nanoparticle comprising a non-tumour protein payload to a subject with cancer, in particular to a cancer cell.
-
公开(公告)号:US11564920B2
公开(公告)日:2023-01-31
申请号:US17731163
申请日:2022-04-27
发明人: Seiji Kamioka , Hitoshi Ban , Makoto Matsuoka , Wataru Hirose , Naoaki Shimada , Kento Hayashi , Hiroki Umehara
IPC分类号: A61K31/497 , A61K31/506 , A61K31/513 , A61K31/519 , A61K31/704 , A61K31/7068 , A61K31/7048 , A61K31/4745 , A61K31/282 , A61K31/337 , A61K31/454 , A61K31/5377 , A61K39/395 , A61K47/24 , A61K47/28 , A61K9/127 , A61K33/243 , A61P35/00
摘要: The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: wherein R1, R2, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CR8 or a nitrogen atom, wherein X, Y, and Z are not simultaneously CR8, and R8 is as defined herein.
-
公开(公告)号:US20220403029A1
公开(公告)日:2022-12-22
申请号:US17727309
申请日:2022-04-22
申请人: Kymab Limited
发明人: Richard Charles Alfred SAINSON , Stephen John ARKINSTALL , Jamie Iain CAMPBELL , Mohammed Hanif ALI , E-Chiang LEE , Matthew John MCCOURT , Nikole SANDY , Cassandra VAN KRINKS , Volker GERMASCHEWSKI , Ian KIRBY , Miha KOSMAC , Thomas GALLAGHER , Cecilia DEANTONIO , Stephen Douglas GILLIES
IPC分类号: C07K16/28 , A61K47/68 , A61P35/00 , A61K31/282 , A61K39/395 , C07K14/55 , C07K16/46 , G01N33/50
摘要: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
-
公开(公告)号:US20220387472A1
公开(公告)日:2022-12-08
申请号:US17770158
申请日:2021-09-21
申请人: AIM ImmunoTech Inc.
发明人: Thomas K. EQUELS , David R. STRAYER
IPC分类号: A61K31/713 , A61K31/519 , A61K31/513 , A61K31/4745 , A61K31/282 , A61P35/00 , A61P1/18 , A61K31/7068
摘要: Disclosed is a method for treating a cancer, such as pancreatic cancer, in a subject. The method comprises a first step of administering to the subject a standard of care therapy such as FOLFIRINOX and administering to the subject a therapeutic double stranded RNA (tdsRNA) which can be Rintatolimod.
-
公开(公告)号:US20220370361A1
公开(公告)日:2022-11-24
申请号:US17864485
申请日:2022-07-14
申请人: PLMICROMED CO., LTD.
发明人: Gwang Suk KIM
IPC分类号: A61K9/16 , A61K31/704 , A61K31/337 , A61K31/4745 , A61K31/7068 , A61K31/282
摘要: The present disclosure provides a biocompatible polymer, and the polymer includes the embolic microbead including an iron adsorption block capable of adsorbing an iron component. The embolic microbead according to the an exemplary embodiment of the present disclosure adsorbs iron and thus effectively blocks an iron component delivered to cancer cells, and when used in embolization, it has an improved effect in treating cancers, such as liver cancer.
-
公开(公告)号:US20220331265A1
公开(公告)日:2022-10-20
申请号:US17531370
申请日:2021-11-19
申请人: Oryzon Genomics S.A.
发明人: Filippo CICERI , Serena LUNARDI , Tamara MAES , Cristina MASCARO CRUSAT , Inigo TIRAPU FERNANDEZ DE LA CUESTA
IPC分类号: A61K31/015 , A61K31/12 , A61K31/282 , A61K31/337 , A61K31/4045 , A61K31/4745 , A61K31/475 , A61K31/519 , A61K31/555 , A61K31/704 , A61K31/7068 , A61K31/19 , A61P35/00 , A61K31/135 , A61K31/17 , A61K31/203 , A61K31/496 , A61K33/36 , A61P35/02 , A61K31/64
摘要: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients (I), pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.
-
公开(公告)号:US11464774B2
公开(公告)日:2022-10-11
申请号:US15763366
申请日:2016-09-30
发明人: John Robert Pollard , Peter Littlewood , Philip Michael Reaper , Mohammed Asmal , Scott Zachary Fields
IPC分类号: A61K31/497 , A61K33/243 , A61P35/00 , A61K45/06 , A61K31/7068 , A61K31/4965 , A61K31/555 , A61K31/519 , A61K31/282 , A61N5/10
摘要: Described herein are methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a DNA damaging agent and between about 12 and about 48 hours later administering to the subject a compound that inhibits ATR protein kinase. Methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a compound that inhibits ATR protein kinase are also described. Exemplary ATR inhibitors are represented by Formulae A-I and A-II or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.
-
10.
公开(公告)号:US20220307034A1
公开(公告)日:2022-09-29
申请号:US17696510
申请日:2022-03-16
发明人: Jianjun Zhao , Jianhong Lin
IPC分类号: C12N15/113 , A61K33/243 , A61K31/7056 , A61K31/506 , A61K31/454 , A61K31/519 , A61K31/549 , A61K31/381 , A61K31/085 , A61K31/427 , A61K31/4985 , A61K31/14 , A61K39/395 , A61K31/282 , A61P13/12
摘要: Provided herein are compositions, systems, articles of manufacture, and methods of treating a subject with: i) an APE2 inhibitor, and ii) a drug agent that causes increased expression of APE2 in said subject. In certain embodiments, the drug agent is Cisplatin or similar drug.
-
-
-
-
-
-
-
-
-